Seong Jinsil, Lee Ik Jae, Shim Su Jung, Lim Do Hoon, Kim Tae Hyun, Kim Jong Hoon, Jang Hong Seok, Kim Mi Sook, Chie Eui Kyu, Kim Jin Hee, Nam Taek-Keun, Lee Hyung Sik, Han Chul Joo
Department of Radiation Oncology, Yonsei University Health System, Seoul, Korea.
Liver Int. 2009 Feb;29(2):147-52. doi: 10.1111/j.1478-3231.2008.01873.x. Epub 2008 Sep 15.
To determine the national practice processes of care and outcomes of radiotherapy for hepatocellular carcinoma (HCC) in Korea.
A national survey of 53 institutions nationwide was conducted by requesting data on their experience of radiotherapy for HCC. Among them, 10 institutions were selected for performing more detailed analysis, based on the radiotherapy experience of at least five HCC patients between 2004 and 2005.
This study covered the treatment of 398 HCC patients for 2 years. Most patients (78%) were in stage III or IV. Radiotherapy was chosen after the failure of other treatments, most frequently transarterial chemoembolization. Radiotherapy was performed predominantly using the three-dimensional conformal technique (3D-CRT, 81.9%) mostly with a total dose of >/=45 Gy. In 9.3% of the patients, radiotherapy was performed using radiosurgery. In a biologically effective dose (BED) with 10 Gy of alpha/beta, 4.2-124.3 Gy(10) was delivered. The median survival time was 12 months, and the 2-year overall survival rate was 27.9%. A tumour size <5 cm, a negative lymph node and BED >53.1 Gy(10) were shown by multivariate analysis to be significant factors for a better prognosis. In a subset analysis for the 326 patients treated with 3D-CRT, better liver function with Child-Pugh class A was shown to be an additional factor for a better prognosis.
Radiotherapy has been used to treat advanced HCC in various modes, but mostly as a salvage treatment. Although this study was retrospective, it indicates that radiotherapy is a quite effective modality for HCC patients.
确定韩国肝细胞癌(HCC)放射治疗的全国护理实践流程及治疗结果。
通过要求全国53家机构提供其HCC放射治疗经验的数据进行全国性调查。其中,基于2004年至2005年间至少5例HCC患者的放射治疗经验,选择10家机构进行更详细的分析。
本研究涵盖了2年期间398例HCC患者的治疗。大多数患者(78%)处于III期或IV期。放射治疗是在其他治疗失败后选择的,最常见的是经动脉化疗栓塞。放射治疗主要采用三维适形技术(3D-CRT,81.9%),总剂量大多≥45 Gy。9.3%的患者采用放射外科进行放射治疗。在α/β为10 Gy的生物等效剂量(BED)下,给予4.2 - 124.3 Gy(10)。中位生存时间为12个月,2年总生存率为27.9%。多因素分析显示,肿瘤大小<5 cm、淋巴结阴性和BED>53.1 Gy(10)是预后较好的重要因素。在对326例接受3D-CRT治疗的患者进行的亚组分析中,Child-Pugh A级肝功能较好是预后较好的另一个因素。
放射治疗已被用于以多种方式治疗晚期HCC,但大多作为挽救性治疗。尽管本研究是回顾性的,但它表明放射治疗对HCC患者是一种相当有效的治疗方式。